The annual BioHealth forum brought together about 1,100 biotech industry stakeholders from across Maryland, Washington, D.C., and Virginia.
George Mason University President Angel Cabrera said more restrictive immigration policies could threaten the future of regional and national biotechnology industries.
“It is critical for universities to act both as producers of [science, technology, engineering and math] talent and as magnets for top STEM faculty and researchers from around the world. That is our biggest role in the ecosystem,” Cabrera said. “When we mess with immigration policy, our whole system of science and innovation is at stake.
Prince William County today congratulated three science start-ups – ISOThrive, LLC, Virongy, LLC and Ceres Nanosciences, Inc., – on recent business successes leading from the Prince William Science Accelerator.
The Emmes Corporation today announced the creation of an internship program in which the company will offer one fellow from Egypt’s Children Cancer Hospital an internship to gain training and experience in clinical research. Under the new program, one fellow will be selected each year to travel to Emmes’ headquarters in Rockville, Maryland, to work with its clinical research experts. The duration of each internship will be determined on a case-by-case basis.
Q Therapeutics, Inc., a developer of clinical-stage cell therapies for central nervous system (CNS) diseases, and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, announced the formation of MAGiQ Therapeutics, Inc., a Japanese joint venture company. MAGiQ will develop iPSC-derived, glial-restricted progenitor cells (GRPs), in collaboration with Q Therapeutics and REPROCELL, to treat demyelinating and degenerative diseases of the CNS.
New York investment firm Deerfield Management is looking to bring more drugs, medical devices and health care products to market by partnering with academic institutions like Johns Hopkins University.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory approval of PartoSureTM , which is a novel test for assessing the risk of spontaneous preterm birth in patients with symptoms of preterm labor. The pre-market approval of PartoSure by the U.S. Food and Drug Administration (FDA) follows successful uptake of the rapid, accurate test in more than 35 countries across Europe, the Middle East, Asia and Latin America. U.S. commercialization of the PartoSure test is expected to begin in 2018.
He is a walking Rolodex of some of the nation’s most high-powered business leaders. And he’s the reason many startups feel they’ve gotten a leg up in an otherwise crushing entrepreneurial race.
Chinese investors are pumping money into US drug startups as Beijing seeks to become a global leader in new medicines, adding to a flood of cash flowing to groundbreaking health firms.
More than a dozen biotech companies or researchers from the Maryland biotech cluster, which some have also dubbed ‘Vaccine Alley’, were among the most recognized finalists at this year’s Vaccine Industry Excellence (ViE) Awards in Washington, DC at the World Vaccine Conference. In fact, 15 out of the 54 finalists, or 27%. were from right here in Maryland. This year’s conference was held in Washington, DC so could this have been a case of home court advantage? Probably not. More than likely it’s because this region holds 20% of the top influencers worldwide in vaccine development.